Acrivon Therapeutics, INC 10-Q quarterly reports

Acrivon Therapeutics, Inc. filed its Q2 2026 Form 10-Q, detailing ongoing clinical development of ACR-368 and ACR-2316, alongside significant operating losses and a projected need for additional funding.

Acrivon Therapeutics reports Q1 2026 results, with continued investment in R&D and a focus on advancing its oncology pipeline, while managing cash runway.

Acrivon Therapeutics, Inc. reported positive clinical data for its lead drug candidates ACR-368 and ACR-2316, while extending its cash runway into Q2 2027 despite continued operating losses.

Acrivon Therapeutics reported increased net losses and cash burn in Q2 2025, while advancing its lead oncology drug candidates ACR-368 and ACR-2316 with positive clinical data.

Acrivon Therapeutics reports a net loss of $19.7 million for Q1 2025, advances clinical programs, and anticipates funding operations into Q2 2027.

Acrivon Therapeutics announced positive clinical data for its lead drug candidate, ACR-368, and progress in its pipeline development during the third quarter of 2024.

Acrivon Therapeutics announced positive initial clinical data from its Phase 2 trial of ACR-368 and provided a financial update, including a private placement that extends their cash runway into the second half of 2026.

Acrivon Therapeutics reported a net loss of $16.5 million for the first quarter of 2024, while highlighting progress in clinical trials and pipeline development.